Article

Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States
Experimental Neurology (Impact Factor: 4.62). 08/2003; 182(1):21-34. DOI: 10.1016/S0014-4886(03)00086-4
Source: PubMed

ABSTRACT The rodent pilocarpine model of epilepsy exhibits hippocampal sclerosis and spontaneous seizures and thus resembles human temporal lobe epilepsy. Use of the many available mouse mutants to study this epilepsy model would benefit from a detailed neuropathology study. To identify new features of epileptogenesis, we characterized glial and neuronal pathologies after pilocarpine-induced status epilepticus (SE) in CF1 and C57BL/6 mice focusing on the hippocampus. All CF1 mice showed spontaneous seizures by 17-27 days after SE. By 6 h there was virtually complete loss of hilar neurons, but the extent of pyramidal cell death varied considerably among mice. In the mossy fiber pathway, neuropeptide Y (NPY) was persistently upregulated beginning 1 day after SE; NPY immunoreactivity in the supragranular layer after 31 days indicated mossy fiber sprouting. beta2 microglobulin-positive activated microglia, normally absent in brains without SE, became abundant over 3-31 days in regions of neuronal loss, including the hippocampus and the amygdala. Astrogliosis developed after 10 days in damaged areas. Amyloid precursor protein immunoreactivity in the thalamus at 10 days suggested delayed axonal degeneration. The mortality after pilocarpine injection was very high in C57BL/6 mice from Jackson Laboratories but not those from Charles River, suggesting that mutant mice in the C57BL/6(JAX) strain will be difficult to study in the pilocarpine model, although their neuropathology was similar to CF1 mice. Major neuropathological changes not previously studied in the rodent pilocarpine model include widespread microglial activation, delayed thalamic axonal death, and persistent NPY upregulation in mossy fibers, together revealing extensive and persistent glial as well as neuronal pathology.

Download full-text

Full-text

Available from: Karin Borges, Nov 20, 2014
0 Followers
 · 
86 Views
  • Source
    • "activation and exacerbate neuroinflammation (Vezzani et al., 2011). In pilocarpine-treated mice evidence of neuroinflammation appears well before injury to most neurons (except perhaps those of the dentate hilus (Borges et al., 2003)), suggesting that in this model the initial cytokine burst elicited by seizures is not caused by neuron loss. In the future it would be worthwhile to explore pharmacological inhibition of EP2 in other models of neuronal injury such as ischemia, AD, PD and ALS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As a prominent inflammatory effector of cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) mediates brain inflammation and injury in many chronic central nervous system (CNS) conditions including seizures and epilepsy, largely through its receptor subtype EP2. However, EP2 receptor activation might also be neuroprotective in models of excitotoxicity and ischemia. These seemingly incongruent observations expose the delicacy of immune and inflammatory signaling in the brain; thus the therapeutic window for quelling neuroinflammation might vary with injury type and target molecule. Here, we identify a therapeutic window for EP2 antagonism to reduce delayed mortality and functional morbidity after status epilepticus (SE) in mice. Importantly, treatment must be delayed relative to SE onset to be effective, a finding that could be explained by the time-course of COX-2 induction after SE and compound pharmacokinetics. A large number of inflammatory mediators were upregulated in hippocampus after SE with COX-2 and IL-1β temporally leading many others. Thus, EP2 antagonism represents a novel anti-inflammatory strategy to treat SE with a tightly-regulated therapeutic window. Copyright © 2015. Published by Elsevier Inc.
    Neurobiology of Disease 01/2015; 76. DOI:10.1016/j.nbd.2014.12.032 · 5.20 Impact Factor
  • Source
    • "BDNF and TGFβ1 were also significantly blunted in the EP1-KO mice compared to wildtype, being reduced by 46% and 36%, respectively. Experiments were then performed to determine the features of glial activation as it is known that astrogliosis and microgliosis are prominent in mice following status epilepticus (Borges et al., 2003; Serrano et al., 2011). The mRNA levels of astrocytic GFAP and microglia IBA1 were measured in brain one day after status epilepticus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostaglandin E2 (PGE2) regulates membrane excitability, synaptic transmission, plasticity, and neuronal survival. The consequences of PGE2 release following seizures has been the subject of much study. Here we demonstrate that the prostaglandin E2 receptor 1 (EP1, or Ptger1) modulates native kainate receptors, a family of ionotropic glutamate receptors widely expressed throughout the central nervous system. Global ablation of the EP1 gene in mice (EP1-KO) had no effect on seizure threshold after kainate injection but reduced the likelihood to enter status epilepticus. EP1-KO mice that did experience typical status epilepticus had reduced hippocampal neurodegeneration and a blunted inflammatory response. Further studies with native prostanoid and kainate receptors in cultured cortical neurons, as well as with recombinant prostanoid and kainate receptors expressed in Xenopus oocytes, demonstrated that EP1 receptor activation potentiates heteromeric but not homomeric kainate receptors via a second messenger cascade involving phospholipase C, calcium and protein kinase C. Three critical GluK5 C-terminal serines underlie the potentiation of the GluK2/GluK5 receptor by EP1 activation. Taken together, these results indicate that EP1 receptor activation during seizures, through a protein kinase C pathway, increases the probability of kainic acid induced status epilepticus, and independently promotes hippocampal neurodegeneration and a broad inflammatory response.
    Neurobiology of Disease 06/2014; 70. DOI:10.1016/j.nbd.2014.06.004 · 5.20 Impact Factor
  • Source
    • "Do Ant-134 mice display reduced hippocampal injury after pilocarpine SE? Unfortunately , too few Scr mice survived SE to enable this analysis in the present study. This was not unexpected, and the pilocarpine model is also associated with high interanimal variability in hippocampal damage (Borges et al. 2003). For related reasons, we do not know if antagomir treatment of mice immediately after pilocarpine-induced SE would alter the later development of epilepsy in this model as was found in the KA model (Jimenez-Mateos et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Emerging data support roles for microRNA (miRNA) in the pathogenesis of various neurologic disorders including epilepsy. MicroRNA-134 (miR-134) is enriched in dendrites of hippocampal neurons, where it negatively regulates spine volume. Recent work identified upregulation of miR-134 in experimental and human epilepsy. Targeting miR-134 in vivo using antagomirs had potent anticonvulsant effects against kainic acid-induced seizures and was associated with a reduction in dendritic spine number. In the present study, we measured dendritic spine volume in mice injected with miR-134-targeting antagomirs and tested effects of the antagomirs on status epilepticus triggered by the cholinergic agonist pilocarpine. Morphometric analysis of over 6,400 dendritic spines in Lucifer yellow-injected CA3 pyramidal neurons revealed increased spine volume in mice given antagomirs compared to controls that received a scrambled sequence. Treatment of mice with miR-134 antagomirs did not alter performance in a behavioral test (novel object location). Status epilepticus induced by pilocarpine was associated with upregulation of miR-134 within the hippocampus of mice. Pretreatment of mice with miR-134 antagomirs reduced the proportion of animals that developed status epilepticus following pilocarpine and increased animal survival. In antagomir-treated mice that did develop status epilepticus, seizure onset was delayed and total seizure power was reduced. These studies provide in vivo evidence that miR-134 regulates spine volume in the hippocampus and validation of the seizure-suppressive effects of miR-134 antagomirs in a model with a different triggering mechanism, indicating broad conservation of anticonvulsant effects.
    Brain Structure and Function 05/2014; DOI:10.1007/s00429-014-0798-5 · 4.57 Impact Factor
Show more